Circulating adrenal and gonadal steroid hormones heterogeneity in active young males and the contribution of 11-oxy androgens.
11-ketotestosterone (11KT)
Androgen replacement therapy
Cytochrome P450 11β hydroxylase (CYP11B1)
Dehydroepiandrosterone (DHEA)
Hypogonadism, 11β-hydroxyandrostenedione (11OHA4 11OHAD11OHAn)
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 Jul 2024
14 Jul 2024
Historique:
received:
06
12
2023
accepted:
03
07
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
epublish
Résumé
The classical androgens, testosterone and dihydrotestosterone, together with dehydroepiandrosterone, the precusrsor to all androgens, are generally included in diagnostic steroid evaluations of androgen excess and deficiency disorders and monitored in androgen replacement and androgen suppressive therapies. The C11-oxy androgens also contribute to androgen excess disorders and are still often excluded from clinical and research-based steroids analysis. The contribution of the C11-oxy androgens to the androgen pool has not been considered in androgen deficiency. An exploratory investigation into circulating adrenal and gonadal steroid hormones in men was undertaken as neither the classical androgens nor the C11-oxy androgens have been evaluated in the context of concurrent measurement of all adrenal steroid hormones. Serum androgens, mineralocorticoids, glucocorticoids, progesterones and androgens were assessed in 70 healthy young men using ultra high performance supercritical fluid chromatography and tandem mass spectrometry. Testosterone, 24.5 nmol/L was the most prominent androgen detected in all participants while dihydrotestosterone, 1.23 nmol/L, was only detected in 25% of the participants. The 11-oxy androgens were present in most of the participants with 11-hydroxyandrostenedione, 3.37 nmol, in 98.5%, 11-ketoandrostenedione 0.764 in 77%, 11-hydroxytestosterone, 0.567 in 96% and 11-ketotestosterone: 0.440 in 63%. A third of the participants with normal testosterone and comparable 11-ketotestosterone, had significantly lower dehydroepiandrosterone (p < 0.001). In these males 11-hydroxyandrostenedione (p < 0.001), 11-ketoandrostenedione (p < 0.01) and 11-hydroxytestosterone (p < 0.006) were decreased. Glucocorticoids were also lower: cortisol (p < 0.001), corticosterone (p < 0.001), cortisone (p < 0.006) 11-dehydrocorticosterone (p < 0.001) as well as cortisol:cortisone (p < 0.001). The presence of dehydroepiandrosterone was associated with 16-hydroxyprogesterone (p < 0.001), which was also significantly lower. Adrenal and gonadal steroid analysis showed unexpected steroid heterogeneity in normal young men. Testosterone constitutes 78% of the circulating free androgens with the 11-oxy androgens abundantly present in all participants significantly contributing 22%. In addition, a subset of men were identified with low circulating dehydroepiandrosterone who showed altered adrenal steroids with decreased glucocorticoids and decreased C11-oxy androgens. Analysis of the classical and 11-oxy androgens with the additional measurement of dehydroepiandrosterone and 16-hydroxyprogesterone may allow better diagnostic accuracy in androgen excess or deficiency.
Identifiants
pubmed: 39003307
doi: 10.1038/s41598-024-66749-9
pii: 10.1038/s41598-024-66749-9
doi:
Substances chimiques
Androgens
0
Testosterone
3XMK78S47O
Gonadal Steroid Hormones
0
Dehydroepiandrosterone
459AG36T1B
11-hydroxyandrostenedione
564-32-9
Androstenedione
409J2J96VR
Dihydrotestosterone
08J2K08A3Y
11-ketotestosterone
KF38W1A85U
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
16226Subventions
Organisme : National Research Foundation
ID : IFR170125217588
Organisme : National Research Foundation
ID : CSUR160414162143
Informations de copyright
© 2024. The Author(s).
Références
Barnard, L., du Toit, T. & Swart, A. C. Back where it belongs, 11β-hydroxyandrostenedione compels the re-assessment of C11-oxy androgens in steroidogenesis. Mol. Cell. Endocrinol. 525, 111189. https://doi.org/10.1016/j.mce.2021.111189 (2021).
doi: 10.1016/j.mce.2021.111189
pubmed: 33539964
Bloem, L. M. et al. Advances in the analytical methodologies: Profiling steroids in familiar pathways-challenging dogmas. J. Steroid Biochem. Mol. Biol. 153, 80–92. https://doi.org/10.1016/j.jsbmb.2015.04.009 (2015).
doi: 10.1016/j.jsbmb.2015.04.009
pubmed: 25869556
Barnard, L., Gent, R., van Rooyen, D. & Swart, A. C. Adrenal C11-oxy C(21) steroids contribute to the C11-oxy C(19) steroid pool via the backdoor pathway in the biosynthesis and metabolism of 21-deoxycortisol and 21-deoxycortisone. J. Steroid Biochem. Mol. Biol. 174, 86–95. https://doi.org/10.1016/j.jsbmb.2017.07.034 (2017).
doi: 10.1016/j.jsbmb.2017.07.034
pubmed: 28774496
van Rooyen, D., Gent, R., Barnard, L. & Swart, A. C. The in vitro metabolism of 11beta-hydroxyprogesterone and 11-ketoprogesterone to 11-ketodihydrotestosterone in the backdoor pathway. J. Steroid Biochem. Mol. Biol. 178, 203–212. https://doi.org/10.1016/j.jsbmb.2017.12.014 (2018).
doi: 10.1016/j.jsbmb.2017.12.014
pubmed: 29277707
Gent, R., du Toit, T., Bloem, L. M. & Swart, A. C. The 11β-hydroxysteroid dehydrogenase isoforms: Pivotal catalytic activities yield potent C11-oxy C19 steroids with 11βHSD2 favouring 11-ketotestosterone, 11-ketoandrostenedione and 11-ketoprogesterone biosynthesis. J. Steroid Biochem. Mol. Biol. 189, 116–126. https://doi.org/10.1016/j.jsbmb.2019.02.013 (2019).
doi: 10.1016/j.jsbmb.2019.02.013
pubmed: 30825506
Bacila, I. et al. Measurement of salivary adrenal-specific androgens as biomarkers of therapy control in 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 104, 6417–6429. https://doi.org/10.1210/jc.2019-00031 (2019).
doi: 10.1210/jc.2019-00031
pubmed: 31361321
Caron, P., Turcotte, V. & Guillemette, C. A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. J. Chromatogr. A. 1650, 462228. https://doi.org/10.1016/j.chroma.2021.462228 (2021).
doi: 10.1016/j.chroma.2021.462228
pubmed: 34090133
Schiffer, L. et al. Multi-steroid profiling by UHPLC-MS/MS with post-column infusion of ammonium fluoride. J. Chromatogr. B 1209, 123413. https://doi.org/10.1016/j.jchromb.2022.123413 (2022).
doi: 10.1016/j.jchromb.2022.123413
Bentley, C. et al. The ultra-acute steroid response to traumatic injury: A cohort study. Eur. J. Endocrinol. 188, 2902–299. https://doi.org/10.1093/ejendo/lvad024 (2023).
doi: 10.1093/ejendo/lvad024
Snaterse, G. et al. 11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration. JCI Insight https://doi.org/10.1172/jci.insight.148507 (2021).
doi: 10.1172/jci.insight.148507
pubmed: 33974560
pmcid: 8262344
Hakkinen, M. R. et al. Simultaneous analysis by LC-MS/MS of 22 ketosteroids with hydroxylamine derivatization and underivatized estradiol from human plasma, serum and prostate tissue. J. Pharm. Biomed. Anal. 164, 642–652. https://doi.org/10.1016/j.jpba.2018.11.035 (2019).
doi: 10.1016/j.jpba.2018.11.035
pubmed: 30472582
du Toit, T. & Swart, A. C. The 11beta-hydroxyandrostenedione pathway and C11-oxy C(21) backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone. J. Steroid Biochem. Mol. Biol. 196, 105497. https://doi.org/10.1016/j.jsbmb.2019.105497 (2020).
doi: 10.1016/j.jsbmb.2019.105497
pubmed: 31626910
du Toit, T. et al. Profiling adrenal 11beta-hydroxyandrostenedione metabolites in prostate cancer cells, tissue and plasma: UPC(2)-MS/MS quantification of 11beta-hydroxytestosterone, 11keto-testosterone and 11keto-dihydrotestosterone. J. Steroid Biochem. Mol. Biol. 166, 54–67. https://doi.org/10.1016/j.jsbmb.2016.06.009 (2017).
doi: 10.1016/j.jsbmb.2016.06.009
pubmed: 27345701
Bae, Y. J. et al. Reference intervals of nine steroid hormones over the life-span analyzed by LC-MS/MS: Effect of age, gender, puberty, and oral contraceptives. J. Steroid Biochem. Mol. Biol. 193, 105409. https://doi.org/10.1016/j.jsbmb.2019.105409 (2019).
doi: 10.1016/j.jsbmb.2019.105409
pubmed: 31201927
Samaras, N., Samaras, D., Frangos, E., Forster, A. & Philippe, J. A. Review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: Is treatment beneficial?. Rejuvenation Res. 16, 285–294. https://doi.org/10.1089/rej.2013.1425 (2013).
doi: 10.1089/rej.2013.1425
pubmed: 23647054
pmcid: 3746247
Zang, T. et al. Simultaneous quantitation of nine hydroxy-androgens and their conjugates in human serum by stable isotope dilution liquid chromatography electrospray ionization tandem mass spectrometry. J. Steroid Biochem. Mol. Biol. 165, 342–355. https://doi.org/10.1016/j.jsbmb.2016.08.001 (2017).
doi: 10.1016/j.jsbmb.2016.08.001
pubmed: 27531846
Cussen, L. et al. Approach to androgen excess in women: Clinical and biochemical insights. Clin. Endocrinol. 97, 174–186. https://doi.org/10.1111/cen.14710 (2022).
doi: 10.1111/cen.14710
Tsametis, C. P. & Isidori, A. M. Testosterone replacement therapy: For whom, when and how?. Metabolism 86, 69–78. https://doi.org/10.1016/j.metabol.2018.03.007 (2018).
doi: 10.1016/j.metabol.2018.03.007
pubmed: 29530796
Handelsman, D. J. The illusory case for treatment of an invented disease. Front. Endocrinol. 12, 682620. https://doi.org/10.3389/fendo.2021.682620 (2021).
doi: 10.3389/fendo.2021.682620
Whitton, K. & Baber, R. Androgen-based therapies in women. Best Pract. Res. Clin. Endocrinol. Metab. 38(1), 101783. https://doi.org/10.1016/j.beem.2023.101783 (2024).
doi: 10.1016/j.beem.2023.101783
pubmed: 37246051
Zumoff, B., Bradlow, H. L., Finkelstein, J., Boyar, R. M. & Hellman, L. The influence of age and sex on the metabolism of testosterone. J. Clin. Endocrinol. Metab. 42, 703–706. https://doi.org/10.1210/jcem-42-4-703 (1976).
doi: 10.1210/jcem-42-4-703
pubmed: 1262444
Burstein, S., Savard, K. & Dorfman, R. I. The in vivo metabolism of 21-desoxycortisone. Endocrinology 53, 267–273. https://doi.org/10.1210/endo-53-3-267 (1953).
doi: 10.1210/endo-53-3-267
pubmed: 13083588
Jailer, J. W., Gold, J. J., Vande Wiele, R. & Lieberman, S. 17alpha-hydroxyprogesterone and 21-desoxyhydrocortisone; their metabolism and possible role in congenital adrenal virilism. J. Clin. Invest. 34, 1639–1646. https://doi.org/10.1172/JCI103217 (1955).
doi: 10.1172/JCI103217
pubmed: 13271547
pmcid: 438744
Ceresini, G. et al. Evaluation of the circadian profiles of serum dehydroepiandrosterone (DHEA), cortisol, and cortisol/DHEA molar ratio after a single oral administration of DHEA in elderly subjects. Metabolism 49, 548–551. https://doi.org/10.1016/s0026-0495(00)80024-4 (2000).
doi: 10.1016/s0026-0495(00)80024-4
pubmed: 10778884
Dahmani, C. et al. Preoperative circulating 11-oxygenated androgens are associated with metastasis-free survival in localized prostate cancer. J. Urol. 209, 337–346. https://doi.org/10.1097/JU.0000000000003049 (2023).
doi: 10.1097/JU.0000000000003049
pubmed: 36373402
Zeidler, R. et al. Inclusion of 11-oxygenated androgens in a clinical routine LC-MS/MS setup for steroid hormone profiling. Int. J. Mol. Sci. https://doi.org/10.3390/ijms24010539 (2022).
doi: 10.3390/ijms24010539
pubmed: 36613983
pmcid: 9820169
du Toit, T., van Rooyen, D., Stander, M. A., Atkin, S. L. & Swart, A. C. Analysis of 52 C(19) and C(21) steroids by UPC(2)-MS/MS: Characterising the C11-oxy steroid metabolome in serum. J. Chromatogr. B 1152, 122243. https://doi.org/10.1016/j.jchromb.2020.122243 (2020).
doi: 10.1016/j.jchromb.2020.122243